Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
OctoPlus
OctoPlus
Activities:
Manufacturing
Drug Delivery
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m
Aims to build a research base in Leiden, The Netherlands
Manufacturing
OctoPlus signs agreement with pharma company to develop controlled release formulation
Of a therapeutic compound for local delivery into joints
Manufacturing
Octoplus extends drug delivery contract with Top-5 pharma company
Will combine product candidate with Octoplus PolyActive drug delivery technology
Research & Development
OctoPlus extends development agreement with ESBATech
For controlled release product for ophthalmic indications
Drug Delivery
OctoPlus appoints ceo
Jan Hendrik Egberts to replace Simon Sturge
Drug Delivery
OctoPlus signs controlled release technology deal with US firm
Will use PolyActive technology to develop compound
Drug Delivery
OctoPlus wins drug delivery contract expansion
Client will proceed with PolyActive technology evaluation
Subscribe now